C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against leishmania major in balb/c mice

PLoS Neglected Tropical Diseases

Volumn 5, Issue 7, 2011, Pages

  Doroud, Delaram ^a,b   Zahedifard, Farnaz ^a   Vatanara, Alireza ^b   Taslimi, Yasaman ^a   Vahabpour, Rouholah ^a   Torkashvand, Fatemeh ^a   Vaziri, Behrooz ^a   Najafabadi, Abdolhossein ^b   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE PROTEINASE; CYSTEINE PROTEINASE TYPE I; CYSTEINE PROTEINASE TYPE II; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; PLASMID DNA; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; LIPOSOME; NANOPARTICLE; PROTOZOAL PROTEIN; PROTOZOAL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG FORMULATION; FEMALE; FLOW CYTOMETRY; IMMUNOGLOBULIN PRODUCTION; INFECTION RESISTANCE; LEISHMANIA MAJOR; LEISHMANIASIS; LIPOSOMAL DELIVERY; MICROTITER PLATE ASSAY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; TH1 CELL; ANIMAL; DISEASE MODEL; GENE DELETION; GENETICS; IMMUNOLOGY; RODENT DISEASE; SKIN LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LIPOSOMES; MICE; MICE, INBRED BALB C; NANOPARTICLES; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RODENT DISEASES; SEQUENCE DELETION; TH1 CELLS;

EID: 79960933515     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001236     Document Type: Article

References (32)

1. Handman E, (2001) Leishmaniasis: Current status of vaccine development. Clin Microb Rev 14: 229-243.
2. Modabber F, Coler R, Reed S, (2010) Vaccines against Leishmania. In: Levine MM, Dougan M, Nabel G, Good MF, Nataro J, Liu MA, editors. New generation vaccines. 4th ed New York, London Informa Healthcare pp. 790-807.
3. Palatnik-de-Sousa CB, (2008) Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26: 1709-1724.
4. Carvalho JA, Rodgers J, Atouguia J, Prazeres DM, Monteiro GA, (2010) DNA vaccines: a rational design against parasitic diseases. Expert Rev Vaccines 9: 175-91.
5. Nguyen DN, Green JJ, Chan JM, Langer R, Anderson DG, (2008) Polymeric materials for gene delivery and DNA vaccination. Adv. Mater 20: 1-21.
6. Copland M J, Rades T, Davies N M, Baird M A, (2005) Lipid based particulate formulations for the delivery of antigen. Immunol Cell Biol 83: 97-105.
7. Muller RH, Mader K, Gohla S, (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 50: 161-177.
8. Joshi MD, Müller RH, (2009) Lipid nanoparticles for parenteral delivery of actives. Eur J Phar Biopharm 71: 161-172.
9. Coombs GH, Mottram JC, (1997) Proteinases of trypanosomes and Leishmania. In: Trypanosomiasis and Leishmaniasis: Biology and Control. Oxford: CAB International p.177.
10. Robertson CD, Coombs GH, North MJ, Mottram JC, (1996) Parasite cysteine proteinases. In: McKerrow JH, James MNG, editors. Perspectives in drug discovery and design vol. 6. ESCOM Science publisher.
11. Sakanari JA, Nadler SA, Chan VJ, Engel JC, Leptak C, et al. (1997) Leishmania major: comparison of the cathepsin L- and B-like cysteine protease genes with those of other trypanosomatids. Exp Parasitol 85: 63-76.
12. Rafati S, Fasel N, Masina S, (2003) Leishmania cysteine proteinases: from gene to subunit vaccine. Curr Genomics 4: 253-61.
13. Rafati S, Zahedifard F, Kakeh Azari M, Taslimi Y, Taheri T, (2008) Leishmania infantum: Prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice. Exp Parasitol 118: 393-401.
14. Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel N, (2001) A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19: 3369-75.
15. Greenland JR, Letvin NL, (2007) Chemical adjuvants for plasmid DNA vaccines. Vaccine 25: 3731-3741.
16. Mutiso JM, Macharia JC, Gicheru MM, (2010) A review of adjuvants for Leishmania vaccine candidates. J Biomed Res 24: 16-25.
17. Doroud D, Vatanara A, Zahedifard F, Gholami E, Vahabpour R, et al. (2010) Cationic Solid Lipid Nanoparticles Loaded by Cysteine Proteinase Genes as a Novel Anti-Leishmaniasis DNA Vaccine Delivery System: Characterization and In Vitro Evaluations. J Pharm Pharmaceut Sci 13: 320-335.
18. Singh N, Gupta R, Jaiswal A K, Sundar S, Dube A, (2009) Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J Antimicrob Chemother 64: 370-4.
19. Viana da costa A, Huerre M, Delacre M, Auriault C, Correia costa J M, et al. (2002) IL-10 leads to a higher parasite persistant mouse model of leishmania major infection. Parasitol Int 51: 367-379.
20. Buffet P A, Sulahian A, Garin YJF, Nassar N, Derouin F, (1995) Culture microtitration: a sensitive method for quantifying leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 39: 2167-2168.
21. Coler R N, Reed S G, (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244-249.
22. Reed SG, Bertholet S, Coler RN, Friede M, (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30: 23-32.
23. Mehta RS, Huang R, Yang M, Zhang XQ, Kolli B, et al. (2008) Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery. Clin Vaccine Immunol 15: 1764-1770.
24. Bolhassani A, Taheri T, Taslimi Y, Zamanilui S, Zahedifard F, et al. (2011) Fluorescent Leishmania species: Development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol 127: 637-645.
25. Cuadros C, Lopez-Hernandez FJ, Dominguez AL, Mc Clelland M, Lustgarten J, (2004) Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 72: 2810-2816.
26. Rafati S, Kariminia A, Seyde-Eslami S, Narimani M, Taheri T, et al. (2002) Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8+ T lymphocytes activation. Vaccine 20: 24-39.
27. Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J, (1998) Cellular immunology and immune regulation: Lipid Vesicle Size Determines the Th1 or Th2 Response to Entrapped Antigen. J Immunol 161: 4000-4007.
28. Klinman DM, Yamshchikov G, Ishigatsubo Y, (1997) Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158: 3635-3639.
29. Wilson KD, de Jong SD, Tam YK, (2009) Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Del Rev 61: 233-242.
30. Xu L, Anchordoquy TJ, (2008) Cholesterol domains in cationic lipid/DNA complexes improve transfection. BBA- Biomembranes 1778: 2177-2181.
31. Seeballuck F, Lawless E, Ashford MB, O'Driscoll CM, (2004) Stimulation of triglyceride-rich lipoprotein secretion by polysorbate 80: in vitro and in vivo correlation using caco-2 cells and a cannulated rat intestinal lymphatic model. Pharm Res 21: 2320-2326.
32. Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD, et al. (2006) Immuno stimulation of dendritic cells by cationic liposomes. Mol membr biol 23: 385-395.